Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists

Radiotherapy plays an important role of managing head and neck squamous cell carcinoma (HNSCC). Concurrent radiotherapy with radiosensitizing cisplastin chemotherapy is the standard of care (SOC) for non-operable locally advanced HNSCC. Cetuximab, a monoclonal antibody of epidermal growth factor rec...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Daniel Tao Xing, Richard Khor, Hui Gan, Morikatsu Wada, Tai Ermongkonchai, Sweet Ping Ng
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	radiotherapy epidermal growth factor receptor immunotherapy cetuximab stereotactic body radiotherapy abscopal effect Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/9e7f46bbe9ad42db9979acc800d8f515
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9e7f46bbe9ad42db9979acc800d8f515
record_format	dspace
spelling	oai:doaj.org-article:9e7f46bbe9ad42db9979acc800d8f5152021-11-25T17:03:08ZRecent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists10.3390/cancers132257162072-6694https://doaj.org/article/9e7f46bbe9ad42db9979acc800d8f5152021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5716https://doaj.org/toc/2072-6694Radiotherapy plays an important role of managing head and neck squamous cell carcinoma (HNSCC). Concurrent radiotherapy with radiosensitizing cisplastin chemotherapy is the standard of care (SOC) for non-operable locally advanced HNSCC. Cetuximab, a monoclonal antibody of epidermal growth factor receptor, was the most extensively studied targeted therapy as a chemo-sparing agent that was used concurrently with radiotherapy. Immunotherapy is used in the treatment of metastatic HNSCC. There is evidence to support the synergistic effect when combining radiotherapy with immunotherapy to potentiate anti-tumor immune response. There has been increasing interest to incorporate immune checkpoint inhibitor (ICI) with radiotherapy in the curative setting for HNSCC. In this review, we discuss the latest evidence that supports concurrent radiotherapy with cisplatin which remains the SOC for locally advanced HNSCC (LA-HNSCC). Cetuximab is suitable for patients who are not fit for cisplatin. We then summarize the clinical trials that incorporate ICI with radiotherapy for LA-HNSCC in concurrent, neoadjuvant, and adjuvant settings. We also discuss the potential of combining immunotherapy with radiotherapy as a treatment de-escalating strategy in HPV-associated oropharyngeal carcinoma. Finally, the pre-clinical and clinical evidence of the abscopal effect when combining stereotactic body radiotherapy with ICIs is presented.Daniel Tao XingRichard KhorHui GanMorikatsu WadaTai ErmongkonchaiSweet Ping NgMDPI AGarticleradiotherapyepidermal growth factor receptorimmunotherapycetuximabstereotactic body radiotherapyabscopal effectNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5716, p 5716 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	radiotherapy epidermal growth factor receptor immunotherapy cetuximab stereotactic body radiotherapy abscopal effect Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	radiotherapy epidermal growth factor receptor immunotherapy cetuximab stereotactic body radiotherapy abscopal effect Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Daniel Tao Xing Richard Khor Hui Gan Morikatsu Wada Tai Ermongkonchai Sweet Ping Ng Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists
description	Radiotherapy plays an important role of managing head and neck squamous cell carcinoma (HNSCC). Concurrent radiotherapy with radiosensitizing cisplastin chemotherapy is the standard of care (SOC) for non-operable locally advanced HNSCC. Cetuximab, a monoclonal antibody of epidermal growth factor receptor, was the most extensively studied targeted therapy as a chemo-sparing agent that was used concurrently with radiotherapy. Immunotherapy is used in the treatment of metastatic HNSCC. There is evidence to support the synergistic effect when combining radiotherapy with immunotherapy to potentiate anti-tumor immune response. There has been increasing interest to incorporate immune checkpoint inhibitor (ICI) with radiotherapy in the curative setting for HNSCC. In this review, we discuss the latest evidence that supports concurrent radiotherapy with cisplatin which remains the SOC for locally advanced HNSCC (LA-HNSCC). Cetuximab is suitable for patients who are not fit for cisplatin. We then summarize the clinical trials that incorporate ICI with radiotherapy for LA-HNSCC in concurrent, neoadjuvant, and adjuvant settings. We also discuss the potential of combining immunotherapy with radiotherapy as a treatment de-escalating strategy in HPV-associated oropharyngeal carcinoma. Finally, the pre-clinical and clinical evidence of the abscopal effect when combining stereotactic body radiotherapy with ICIs is presented.
format	article
author	Daniel Tao Xing Richard Khor Hui Gan Morikatsu Wada Tai Ermongkonchai Sweet Ping Ng
author_facet	Daniel Tao Xing Richard Khor Hui Gan Morikatsu Wada Tai Ermongkonchai Sweet Ping Ng
author_sort	Daniel Tao Xing
title	Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists
title_short	Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists
title_full	Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists
title_fullStr	Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists
title_full_unstemmed	Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists
title_sort	recent research on combination of radiotherapy with targeted therapy or immunotherapy in head and neck squamous cell carcinoma: a review for radiation oncologists
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/9e7f46bbe9ad42db9979acc800d8f515
work_keys_str_mv	AT danieltaoxing recentresearchoncombinationofradiotherapywithtargetedtherapyorimmunotherapyinheadandnecksquamouscellcarcinomaareviewforradiationoncologists AT richardkhor recentresearchoncombinationofradiotherapywithtargetedtherapyorimmunotherapyinheadandnecksquamouscellcarcinomaareviewforradiationoncologists AT huigan recentresearchoncombinationofradiotherapywithtargetedtherapyorimmunotherapyinheadandnecksquamouscellcarcinomaareviewforradiationoncologists AT morikatsuwada recentresearchoncombinationofradiotherapywithtargetedtherapyorimmunotherapyinheadandnecksquamouscellcarcinomaareviewforradiationoncologists AT taiermongkonchai recentresearchoncombinationofradiotherapywithtargetedtherapyorimmunotherapyinheadandnecksquamouscellcarcinomaareviewforradiationoncologists AT sweetpingng recentresearchoncombinationofradiotherapywithtargetedtherapyorimmunotherapyinheadandnecksquamouscellcarcinomaareviewforradiationoncologists
_version_	1718412792565858304

Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists

Ejemplares similares